bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.47 USD
-0.02 (-4.43%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.48 +0.01 (2.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
BLUE 0.47 -0.02(-4.43%)
Will BLUE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLUE
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Other News for BLUE
Bluebird: Q1 Earnings Snapshot
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
bluebird bio completes restated 10-K, delays 2024 Q2 10-Q
bluebird bio Announces September Investor Events